Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Lenalidomide in Relapsed and Refractory Multiple Myeloma Disease: Feasibility and Benefits of Long-Term Treatment

Katharina Oehrlein, MD, Corinna Rendl, Corinna Hahn-Ast, Lothar Kanz, MD, Katja C Weisel, MD

Blood (2012) 120 (21): 4069.

https://doi.org/10.1182/blood.V120.21.4069.4069

Published: 2012

Journal Articles

Outcome of Fungal Infection in Patients Undergoing Myelosuppressive Chemotherapy in a Tertiary Care Centre During 12 Years (1995-2006).

Marie von Lilienfeld-Toal, MD, Axel Glasmacher, MD, Günter Marklein, MD, Peter Brossart, MD, Corinna Hahn-Ast, PhD

Blood (2009) 114 (22): 1384.

https://doi.org/10.1182/blood.V114.22.1384.1384

Published: 2009

Journal Articles

Longer Duration of Thalidomide Monotherapy Results in Improved Outcome in Relapsed/Refractory Multiple Myeloma.

Blood (2007) 110 (11): 2725.

https://doi.org/10.1182/blood.V110.11.2725.2725

Published: 2007

Journal Articles

Multicenter Phase II Trial of Patients with Refractory or Recurrent Multiple Myeloma with Oral Treatment of Thalidomide Combined with Oral Cyclophosphamide, Idarubicin and Dexamethasone.

Axel Glasmacher, MD, Thomas Moehler, MD, Hartmut Goldschmidt, MD, Thomas Geer, MD, Rolf Kleinschmidt, MD, Tobias Gaska, MD, Janssens Uwe, MD, Jorg Schubert, MD, Patrick Bruck, MD, Michael R. Clemens, MD, Wolfgang Bair, MD, Gernot Seipelt, MD, Michael Schleuning, MD, Corinna Hahn-Ast, PhD, Susanne Herz, Marie von Lilienfeld-Toal, MD, Ralf Naumann, MD, Marcus Gorschluter, MD, Ingo G.H. Schmidt-Wolf, MD

Blood (2007) 110 (11): 4825.

https://doi.org/10.1182/blood.V110.11.4825.4825

Published: 2007

Journal Articles

Multicenter Phase II Trial of Patients with Refractory or Recurrent Multiple Myeloma with Oral Treatment of Thalidomide Combined with Oral Cyclophosphamide, Idarubicin and Dexamethasone.

Ingo G.H. Schmidt-Wolf, MD, Thomas Moehler, MD, Hartmut Goldschmidt, MD, Thomas Geer, MD, Rolf Kleinschmidt, MD, Tobias Gaska, MD, Uwe Janssens, MD, Joerg Schubert, MD, Patrick Brueck, MD, Michael R. Clemens, MD, Wolfgang Bair, MD, Gernot Seipelt, MD, Michael Schleuning, MD, Corinna Hahn-Ast, Ph.D., Susanne Herz, Ph.D., Marie von Lilienfeld-Toal, M.D., Ralph Naumann, MD, Marcus Gorschlueter, MD, Axel Glasmacher, MD

Blood (2006) 108 (11): 3559.

https://doi.org/10.1182/blood.V108.11.3559.3559

Published: 2006

Journal Articles

Remission Induction with Cladribine, Cytarabine and Idarubicin (CAI) in Elderly Patients with Relapsed AML - A Pilot Study.

Marie von Lilienfeld-Toal, MD, Corinna Hahn-Ast, PhD, Katjana Orlopp, MD, Schmidt-Wolf G.H. Ingo, MD, Glasmacher Axel, MD

Blood (2006) 108 (11): 4570.

https://doi.org/10.1182/blood.V108.11.4570.4570

Published: 2006

NARROW

Lenalidomide in Relapsed and Refractory Multiple Myeloma Disease: Feasibility and Benefits of Long-Term Treatment

Outcome of Fungal Infection in Patients Undergoing Myelosuppressive Chemotherapy in a Tertiary Care Centre During 12 Years (1995-2006).

Longer Duration of Thalidomide Monotherapy Results in Improved Outcome in Relapsed/Refractory Multiple Myeloma.

Multicenter Phase II Trial of Patients with Refractory or Recurrent Multiple Myeloma with Oral Treatment of Thalidomide Combined with Oral Cyclophosphamide, Idarubicin and Dexamethasone.

Multicenter Phase II Trial of Patients with Refractory or Recurrent Multiple Myeloma with Oral Treatment of Thalidomide Combined with Oral Cyclophosphamide, Idarubicin and Dexamethasone.

Remission Induction with Cladribine, Cytarabine and Idarubicin (CAI) in Elderly Patients with Relapsed AML - A Pilot Study.

Email alerts

ASH Publications

American Society of Hematology

Lenalidomide in Relapsed and Refractory Multiple Myeloma Disease: Feasibility and Benefits of Long-Term Treatment

Outcome of Fungal Infection in Patients Undergoing Myelosuppressive Chemotherapy in a Tertiary Care Centre During 12 Years (1995-2006).

Longer Duration of Thalidomide Monotherapy Results in Improved Outcome in Relapsed/Refractory Multiple Myeloma.

Multicenter Phase II Trial of Patients with Refractory or Recurrent Multiple Myeloma with Oral Treatment of Thalidomide Combined with Oral Cyclophosphamide, Idarubicin and Dexamethasone.

Multicenter Phase II Trial of Patients with Refractory or Recurrent Multiple Myeloma with Oral Treatment of Thalidomide Combined with Oral Cyclophosphamide, Idarubicin and Dexamethasone.

Remission Induction with Cladribine, Cytarabine and Idarubicin (CAI) in Elderly Patients with Relapsed AML - A Pilot Study.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only